Research  >  Research  >  Scientist Profiles  >  Scientists A-F

Scientist profiles A-F

SRI profiles

Matthew Cheung, MD, FRCPC, SM

Associate scientist

Odette Cancer Centre
Sunnybrook Health Sciences Centre
2075 Bayview Ave., Room T2-044
Toronto, ON
M4N 3M5

Phone: 416-480-4928
Fax: 416-480-6002


  • MD, 1999, University of Toronto, Canada
  • FRCPC, 2002, internal medicine, U of T, Canada
  • FRCPC, 2004, adult hematology, U of T, Canada
  • SM (Master of Science), 2006, epidemiology, Harvard School of Public Health, U.S.
  • Clinical and research fellowship, 2007, lymphoma, U of T, Canada
  • Postdoctoral research fellowship, 2007, human immunodeficiency virus and acquired immunodeficiency syndrome, Canadian Institutes of Health Research, Canada

Appointments and Affiliations:

  • Associate scientist, Evaluative Clinical Sciences, Odette Cancer Research Program, Sunnybrook Research Institute
  • Professor, department of medicine, division of hematology, U of T
  • Adjunct scientist, Institute for Clinical Evaluative Sciences
  • Co-chair, work-up of lymphoma guideline group, ASH/CAP/ASCP
  • Clinical hematologist, Odette Cancer Centre, Sunnybrook Health Sciences Centre
  • Co-chair, hematology disease site group, Cancer Care Ontario
  • Executive member, pan-Canadian Oncology Drug Review
  • Executive member, hematology site group, National Cancer Institute of Canada Clinical Trials Group
  • Member, committee on practice, American Society of Hematology
  • Member, palliative care working group, American Society of Hematology

Research Summary:

Dr. Cheung's areas of research include economic evaluations embedded into clinical trials, health outcomes research in hematologic malignancies, and clinical trials in lymphoma. He holds peer-reviewed grants from the Canadian Institutes of Health Research, the National Cancer Institute of Canada and the Canadian Foundation for AIDS Research.

Selected Publications:

See current publications list at PubMed.

  1. Cheung MC, Earle CC, Fischer HD, Camacho X, Liu N, Saskin R, Shah BR, Austin PC, Singh S. Impact of immigration status on cancer outcomes in Ontario, Canada. J Oncol Pract. 2017 Jul;13(7):e602–e612.
  2. Cheung MC, Sabharwal M, Chambers A, Han D, Sabarre KA, Chan K. Multiple dimensions of value: evaluative frameworks for new cancer therapies. J Clinical Onc. 2016 Apr 20;34(12):1428–1429.
  3. Cheung MC, Earle CC, Rangrej J, Ho TH, Liu N, Barbera L, Saskin R, Porter J, Seung SJ, Mittmann N. Impact of aggressive management and palliative care on cancer costs in the final month of life. Cancer. 2015 Sep 15;121(18):3307–15.
  4. Cheung MC, Mittmann N, Shepherd L, Risebrough N, Imrie KR, Hay AE, Djurfeldt M, Meyer RM, Chen BE, Crump M. Gemcitabine/dexamethasone/cisplatin vs. cytarabin/dexamethasone/cisplatin for relapsed or refractory aggressive-histology lymphoma: cost-utility analysis of NCIC CTG LY.12. J Natl Cancer Inst. 2015 Apr 13;107(7).
  5. Crump M, Herst J, Baldassarre F, Sussman J, MacEachern J, Hodgson D, Cheung MC. Evidence-based focused review of the role of radiation therapy in the treatment of early-stage Hodgkin lymphoma. Blood. 2015 Mar 12;125(11):1708–16.
  6. Nikonova A, Guirguis HR, Buckstein R, Cheung MC. Predictors of delay in diagnosis and treatment in diffuse large B-cell lymphoma and impact on survival. British Journal of Haematology 2015 Feb; 168(4):492–500.
  7. Prica A, Chan K, Cheung MC. Combined modality therapy versus chemotherapy alone as an induction regimen for primary central nervous system lymphoma: a decision analysis. Br J Haematol. 2012 Sep;158(5):600–7.

Related News and Stories:

Related Links